1-(iodomethyl)-3-(trifluoromethyl)benzene | 120276-50-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(iodomethyl)-3-(trifluoromethyl)benzene
• CAS: 120276-50-8
• 化学式: C₈H₆F₃I
• 分子量: 286.035
• InChiKey: IVKYQEFSFQLTHM-UHFFFAOYSA-N

物化性质

• 沸点：
  217.9±40.0 °C(Predicted)
• 密度：
  1.809±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(iodomethyl)-3-(trifluoromethyl)benzene 在 copper(l) iodide 、 1,10-菲罗啉 、 草酰氯 、 水 、 caesium carbonate 、 sodium hydroxide 作用下， 以 1,4-二氧六环 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 45.0h， 生成 bis(2,4,6-trichlorophenyl) 2-(3-trifluoromethylphenyl)malonate
  参考文献：
  名称：

  嘧啶嗡盐类化合物合成及应用

  摘要：

  本发明涉及一种嘧啶嗡盐类化合物合成及应用；具体地，本发明涉及式(I)所示的介离子衍生物或式(I)所示介离子衍生物的立体异构体、氮氧化物或其盐，及介离子衍生物的制备方法，及它们在农业中作为杀虫剂的用途，及其杀虫剂组合物的形式，以及用这些化合物或组合物来杀灭害虫的方法；其中，R1、R2、R3、R4、R5、R6和R7具有本发明所述的含义。

  公开号：

  CN112574194A
• 作为产物：
  描述：

  1-氯甲基-3-三氟甲基苯 在 sodium iodide 作用下， 以 丙酮 为溶剂， 反应 16.0h， 以53%的产率得到1-(iodomethyl)-3-(trifluoromethyl)benzene
  参考文献：
  名称：

  在Barbier条件下通过碘-锂交换反应连续流制备（杂）苄基锂。

  摘要：

  在这里，我们报告了通过使用t BuLi作为交换试剂在连续流动下进行的苄基碘化物上的碘-锂交换反应生成苄基锂。在Barbier条件下，羰基亲电试剂将所得的苄基锂物质原位捕获，从而生成苄基仲和叔醇。该流动程序进一步允许产生高反应性的杂苄基锂化合物，其在间歇条件下难以产生。无需进一步优化，就可以进行总体放大。

  DOI：

  10.1021/acs.orglett.0c01991

文献信息

• [EN] N-HYDROXY-NAPHTHALENE DICARBOXAMIDE AND N-HYDROXY-BIPHENYL-DICARBOXAMIDE COMPOUNDS AS HISTONE DEACETYLASE INHIBITORS<br/>[FR] COMPOSÉS N-HYDROXY-NAPHTALÈNE DICARBOXAMIDE ET N-HYDROXY-BIPHÉNYL-DICARBOXAMIDE COMME INHIBITEURS DE L'HISTONE DÉSACÉTYLASE
  申请人：MERCK & CO INC

  公开号：WO2009045385A1

  公开（公告）日：2009-04-09

  The present invention relates to a novel class of N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can be used to treat cancer. The N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide compounds can also inhibit histone deacetylase and are suitable for use in selectively inducing terminal differentiation, and arresting cell growth and/or apoptosis of neoplastic cells, thereby inhibiting proliferation of such cells. Thus, the compounds of the present invention are useful in treating a patient having a tumor characterized by proliferation of neoplastic cells. The compounds of the invention may also be useful in the prevention and treatment of TRX-mediated diseases, such as autoimmune, allergic and inflammatory diseases, and in the prevention and/or treatment of diseases of the central nervous system (CNS), such as neurodegenerative diseases. The present invention further provides pharmaceutical compositions comprising the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives and safe dosing regimens of these pharmaceutical compositions, which are easy to follow, and which result in a therapeutically effective amount of the N-hydroxy-naphthalene dicarboxamide and N-hydroxy-biphenyl-dicarboxamide derivatives in vivo.

  本发明涉及一类新型的N-羟基-萘二甲酰胺和N-羟基联苯二甲酰胺衍生物。N-羟基-萘二甲酰胺和N-羟基联苯二甲酰胺化合物可用于治疗癌症。N-羟基-萘二甲酰胺和N-羟基联苯二甲酰胺化合物还可以抑制组蛋白去乙酰化酶，并适用于选择性诱导末端分化、阻止肿瘤细胞生长和/或凋亡，从而抑制这些细胞的增殖。因此，本发明的化合物可用于治疗具有肿瘤细胞增殖特征的患者。本发明的化合物也可用于预防和治疗TRX介导的疾病，如自身免疫、过敏和炎症性疾病，以及中枢神经系统（CNS）疾病的预防和/或治疗，如神经退行性疾病。本发明还提供包含N-羟基-萘二甲酰胺和N-羟基联苯二甲酰胺衍生物的制药组合物和这些制药组合物的安全用量方案，易于遵循，并在体内产生治疗有效量的N-羟基-萘二甲酰胺和N-羟基联苯二甲酰胺衍生物。
• Therapeutic preparations
  申请人：IMPERIAL CHEMICAL INDUSTRIES PLC

  公开号：EP0284174A1

  公开（公告）日：1988-09-28

  The invention concerns pharmaceutical compositions containing a 1,2-dihydro-3H-indazol-3-one derivative of the formula I wherein Ra is hydrogen, halogeno, nitro, hydroxy, (2-6C)alkanoyloxy, (1-6C)alkyl, (1-6C)alkoxy, fluoro-(1-4C)alkyl, (2-6C)alkanoyl, amino, (1-6C)alkylamino, di-[(1-4C)alkyl]amino, (2-6C)alkanoylamino or hydroxy-­(1-6C)alkyl; Rb is hydrogen, halogeno, (1-6C)alkyl or (1-6C)alkoxy; and Y is a group of the formula -A¹-X-A²-Q in which A¹ is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene, or A¹ is phenylene; X is oxy, thio, sulphinyl, sulphonyl, imino, (1-­6C)alkylimino, (1-6C)alkanoylimino, iminocarbonyl or phenylene, or X is a direct link to A²; A² is (1-6C)alkylene, (3-6C)alkenylene or (3-­6C)alkynylene or A² is cyclo(3-6C)alkylene or is a direct link to Q, or the group A¹-X-A² is a direct link to Q; or Y is (2-10)alkyl, (3-­10C)alkenyl or (3-6C)alkynyl; and Q is aryl or heteroaryl. The invention also provides novel 1,2-dihydro-3H-indazol-3-­ones, processes for their production and the use of 1,2-dihydro-3H-­indazol-3-one for the manufacture of medicaments for the treatment of various allergic and inflammatory diseases.

  本发明涉及含有式 I 的 1,2-二氢-3H-吲唑-3-酮衍生物的药物组合物 其中Ra是氢、卤素、硝基、羟基、(2-6C)烷酰氧基、(1-6C)烷基、(1-6C)烷氧基、氟-(1-4C)烷基、(2-6C)烷酰基、氨基、(1-6C)烷基氨基、二[(1-4C)烷基]氨基、(2-6C)烷酰氨基或羟基-(1-6C)烷基；Rb 是氢、卤素、(1-6C)烷基或 (1-6C)烷氧基；以及 Y 是式 -A¹-X-A²-Q 的基团，其中 A¹ 是 (1-6C)亚烷基、(3-6C)烯基、(3-6C)炔基或环(3-6C)亚烷基，或 A¹ 是亚苯基；X 是氧基、硫代、亚砜基、磺酰基、亚氨基、(1-6C)烷基亚氨基、(1-6C)烷酰亚氨基、亚氨基羰基或亚苯基，或 X 是与 A² 的直接连接；A²是(1-6C)亚烷基、(3-6C)亚烯基或(3-6C)亚炔基，或A²是环(3-6C)亚烷基，或与Q直接相连，或基团A¹-X-A²与Q直接相连；或Y是(2-10)烷基、(3-10C)亚烯基或(3-6C)亚炔基；且Q是芳基或杂芳基。 本发明还提供了新型 1,2-二氢-3H-吲唑-3-酮、其生产工艺以及 1,2-二氢-3H-吲唑-3-酮用于制造治疗各种过敏性和炎症性疾病的药物。
• [EN] QUINAZOLINE COMPOUND, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF<br/>[FR] COMPOSÉ DE QUINAZOLINE, SON PROCÉDÉ DE PRÉPARATION ET SON APPLICATION<br/>[ZH] 一种喹唑啉类化合物、其制备方法及其应用
  申请人：[en]SHANGHAI PHARMACEUTICALS HOLDING CO., LTD.;[zh]上海医药集团股份有限公司

  公开号：WO2022237903A1

  公开（公告）日：2022-11-17

  提供了一种喹唑啉类化合物及其应用，具体提供了一种如式I所示的喹唑啉类化合物，所述化合物结构新颖，对细胞因子TNF-α，IL-6，IL-1β具有良好的抑制效果。
• 1,3,8-Triazaspiro[4.5]decane-2,4-diones as Efficacious Pan-Inhibitors of Hypoxia-Inducible Factor Prolyl Hydroxylase 1–3 (HIF PHD1–3) for the Treatment of Anemia
  作者：Petr Vachal、Shouwu Miao、Joan M. Pierce、Deodial Guiadeen、Vincent J. Colandrea、Matthew J. Wyvratt、Scott P. Salowe、Lisa M. Sonatore、James A. Milligan、Richard Hajdu、Anantha Gollapudi、Carol A. Keohane、Russell B. Lingham、Suzanne M. Mandala、Julie A. DeMartino、Xinchun Tong、Michael Wolff、Dietrich Steinhuebel、Gerard R. Kieczykowski、Fred J. Fleitz、Kevin Chapman、John Athanasopoulos、Gregory Adam、Can D. Akyuz、Dhirendra K. Jena、Jeffrey W. Lusen、Juncai Meng、Benjamin D. Stein、Lei Xia、Edward C. Sherer、Jeffrey J. Hale

  DOI：10.1021/jm201542d

  日期：2012.4.12

  The discovery of 1,3,8-triazaspiro[4.5]decane-2,4-diones (spirohydantoins) as a structural class of pan-inhibitors of the prolyl hydroxylase (PHD) family of enzymes for the treatment of anemia is described. The initial hit class, spirooxindoles, was identified through affinity selection mass spectrometry (AS-MS) and optimized for PHD2 inhibition and optimal PK/PD profile (short-acting PHDi inhibitors). 1,3,8-Triazaspiro[4.5]decane-2,4-diones (spirohydantoins) were optimized as an advanced lead class derived from the original spiroindole hit. A new set of general conditions for C-N coupling, developed using a high-throughput experimentation (HTE) technique, enabled a full SAR analysis of the spirohydantoins. This rapid and directed SAR exploration has resulted in the first reported examples of hydantoin derivatives with good PK in preclinical species. Potassium channel off-target activity (hERG) was successfully eliminated through the systematic introduction of acidic functionality to the molecular structure. Undesired upregulation of alanine aminotransferese (ALT) liver enzymes was mitigated and a robust on-/off-target margin was achieved. Spirohydantoins represent a class of highly efficacious, short-acting PHD1-3 inhibitors causing a robust erythropoietin (EPO) upregulation in vivo in multiple preclinical species. This profile deems spirohydantoins as attractive short-acting PHDi inhibitors with the potential for treatment of anemia.
• THIAZOLOPYRIMIDINONE DERIVATIVES AS PI3 KINASE INHIBITORS
  申请人：GlaxoSmithKline LLC

  公开号：EP2432321B1

  公开（公告）日：2017-06-14